A database of FDA approved therapeutic peptides and proteins
ID1537 | ThPPIDTh1116 | NameCanakinumab | Peptide SequenceH-GAMMA-1 (VH(1-118) Full view | Length842 | Functional ClassificationIIIb | DiseaseImmunological | BrandILARIS | CompanyNovartis Pharmaceuticals | Physical AppearanceWhite, preservative-free, lyophilized powder | Route of AdministartionSubcutaneous injection | CategoryAnti-Inflammatory Agents and Monoclonal antibodies | TargetInterleukin-1 beta |
ID1767 | ThPPIDTh1185 | NameHuman clostridium tetani toxoid immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseInfectious Disease | BrandHypertet S/d | CompanyGRIFOLS USA, LLC | Physical AppearanceInjection | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1772 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandHyp Rho D Inj 16.5% | CompanyCutter Med & Biol, Division Of Miles Canada Ltd. | Physical Appearanceliquid | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1773 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandHyperrho S/d Full Dose | CompanyGRIFOLS USA, LLC | Physical AppearanceSoution | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1774 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandHyperrho S/d Mini-dose | CompanyGRIFOLS USA, LLC | Physical AppearanceSolution | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1775 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandMicrhogam Ultra-filtered Plus | CompanyKedrion Melville, Inc. | Physical AppearanceInjection, Solution | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1776 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandRhogam Ultra-filtered Plus | CompanyKedrion Melville, Inc. | Physical AppearanceInjection, Solution | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1777 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandRhophylac | CompanyCsl Behring Ag | Physical AppearanceSolution | Route of AdministartionIntramuscular; Intravenous | CategoryNA | TargetNA |
ID1778 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandWinrho Sdf | CompanyAptevo Biotherapeutics Llc | Physical Appearancekit | Route of AdministartionIntramuscular; Intravenous | CategoryNA | TargetNA |
ID1779 | ThPPIDTh1187 | NameHuman Rho(D) immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandWinrho Sdf (liquid Formulation) | CompanyAptevo Biotherapeutics Llc | Physical Appearanceliquid | Route of AdministartionIntramuscular; Intravenous | CategoryNA | TargetNA |
ID1785 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandBivigam | CompanyKedrion Biopharma, Inc. | Physical AppearanceInjection, Solution | Route of AdministartionIntravenous | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1786 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandBivigam | CompanyBiotest Pharmaceuticals Corporation | Physical AppearanceInjection, Solution | Route of AdministartionIntravenous | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1788 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandCarimune Nanofiltered | CompanyCsl Behring Ag | Physical AppearanceInjection, Powder, Lyophilized, for Solution | Route of AdministartionIntravenous | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1791 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandFlebogamma Dif | CompanyGRIFOLS USA, LLC | Physical AppearanceInjection, Solution | Route of AdministartionIntravenous | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1793 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandGamastan | CompanyCutter Med & Biol, Division Of Miles Canada Ltd. | Physical Appearanceliquid | Route of AdministartionIntramuscular | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1794 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandGamastan S/d | CompanyGRIFOLS USA, LLC | Physical AppearanceInjection | Route of AdministartionIntramuscular | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1795 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandHyqvia | CompanyBaxalta Us Inc. | Physical AppearanceLiquid | Route of AdministartionIntravenous infusion | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1796 | ThPPIDTh1190 | NameImmune Globulin Human | Peptide SequenceIGG1: PSALTQPPSASGSL Full view | Length1338 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandIveegam Immuno 5000mg (iv) | CompanyBaxter Ag | Physical AppearanceNA | Route of AdministartionNA | CategoryImmunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | TargetHigh affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
ID1798 | ThPPIDTh1192 | NameUstekinumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseInfectious Disease | BrandStelara | CompanyJanssen Biotech, Inc. | Physical AppearanceSolution fro Injection | Route of AdministartionSubcutaneous | CategoryDeramtologic agent, Immunosuppressive agent, antineoplastic agent | TargetInterleukin-12 subunit beta |
ID1828 | ThPPIDTh1218 | NameAnti-thymocyte Globulin (Equine) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandATGAM | CompanyNA | Physical Appearance Solid | Route of Administartion Intravenous | CategoryAntibody | TargetNA |
ID1829 | ThPPIDTh1219 | NameAnti-thymocyte Globulin (Rabbit) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseImmunological Disorders | BrandATG-Fresenius | CompanyGenzyme Inc. | Physical AppearanceConcentrate for solution for infusion. | Route of Administartion Intravenous | CategoryAntibody | TargetT-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3 |